Serum interleukin-27 expression in patients with myasthenia gravis

J Neuroimmunol. 2015 Nov 15:288:120-2. doi: 10.1016/j.jneuroim.2015.09.010. Epub 2015 Sep 28.

Abstract

Myasthenia gravis (MG)(1) is an autoimmune disease directed at the neuromuscular junction, and cytokines are thought to contribute to its immunopathogenesis. Interleukin-27 (IL-27)(2) plays a complex and pleiotropic role in immune responses associated with T helper cells. To assess the role of IL-27 in MG, we determined serum IL-27 levels in MG patients (n=32) compared to healthy controls (n=50). The median serum IL-27 level was significantly higher in MG patients (35.947pg/mL) than in controls (19.885pg/mL). Furthermore, serum IL-27 was significantly higher in early onset MG. This study suggests the possibility that IL-27 might contribute to MG pathogenesis or immunoregulation.

Keywords: Interleukin-27; Myasthenia gravis; Pathogenesis.

MeSH terms

  • Adult
  • Female
  • Humans
  • Interleukins / blood*
  • Male
  • Middle Aged
  • Myasthenia Gravis / blood*

Substances

  • Interleukins
  • MYDGF protein, human